AVORO CAPITAL ADVISORS LLC 13D and 13G filings for Xenon Pharmaceuticals Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-14 09:12 am Purchase |
2023-12-31 | 13G | Xenon Pharmaceuticals Inc. XENE |
AVORO CAPITAL ADVISORS LLC | 5,666,666 7.700% |
766,666 (+15.65%) |
Filing |
| 2023-02-14 09:41 am Sale |
2022-12-31 | 13G | Xenon Pharmaceuticals Inc. XENE |
AVORO CAPITAL ADVISORS LLC | 4,900,000 7.800% |
-85,000 (-1.71%) |
Filing |
| 2022-02-11 10:00 am Purchase |
2021-12-31 | 13G | Xenon Pharmaceuticals Inc. XENE |
AVORO CAPITAL ADVISORS LLC | 4,985,000 9.700% |
2,185,000 (+78.04%) |
Filing |
| 2021-02-12 08:14 am Purchase |
2020-12-31 | 13G | Xenon Pharmaceuticals Inc. XENE |
AVORO CAPITAL ADVISORS LLC | 2,800,000 8.000% |
400,000 (+16.67%) |
Filing |